Andrew Berens analyst

Currently out of the existing stock ratings of Andrew Berens, 154 are a BUY (68.75%), 49 are a HOLD (21.88%), 21 are a SELL (9.38%).

Andrew Berens

Work Performance Price Targets & Ratings Chart

Analyst Andrew Berens, currently employed carries an average stock price target met ratio of 55.19% that have a potential upside of 31.71% achieved within 226 days. Previously, Andrew Berens worked at LEERINK.

Andrew Berens’s has documented 440 price targets and ratings displayed on 38 stocks. The coverage was on Healthcare, Basic Materials sectors.

Most recent stock forecast was given on ZYME, Zymeworks . Common Stock at 07-Nov-2024.

Wall Street Analyst Andrew Berens

Analyst best performing recommendations are on ELEV (ELEVATION ONCOLOGY).
The best stock recommendation documented was for ELEV (ELEVATION ONCOLOGY) at 1/9/2023. The price target of $1 was fulfilled within 3 days with a profit of $0.2 (25%) receiving and performance score of 83.33.

Average potential price target upside

AGIO Agios Pharm AVEO AVEO Pharmaceuticals BGNE BeiGene Ltd BPMC Blueprint Medicines Corp DCPH Deciphera Pharmaceuticals LLC EPZM Epizyme FMTX Forma Therapeutics Holdings GPRE Green Plains Renewable Energy INCY yte MRTX Mirati Ther SGEN Seagen ZNTL Zentalis Pharmaceuticals Llc ZYME Zymeworks . Common Stock AZN AstraZeneca PLC ADR CLVS Clovis Oncology GILD Gilead Sciences GWPH GW Pharmaceuticals plc HOOK Hookipa Pharma ARVN Arvinas GBT Global Blood Therapeutics ICPT Intercept Pharmaceuticals MRUS Merus BV OCUL Ocular Therapeutix RLYP Relypsa CGEM Cullinan Oncology LLC CMPX Compass Therapeutics . GLUE Monte Rosa Therapeutics TNGX Tango Therapeutics TPTX Turning Point Therapeutics NRIX Nurix Therapeutics  COGT Cogent Biosciences ELEV Elevation Oncology AURA Aura Biosciences RMTI Rockwell Medical THRX Theseus Pharmaceuticals CTIC CTi Biopharma Corp REGN Regeneron Pharmaceuticals VIRX Viracta Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$53

$-0.78 (-1.45%)

$51

16 days ago
(01-Nov-2024)

6/6 (100%)

$8.13 (18.12%)

477

Buy

$56

$2.22 (4.13%)

$37

1 months 21 days ago
(27-Sep-2024)

9/12 (75%)

$10.39 (22.78%)

227

Hold

$46

$-7.78 (-14.47%)

$30

5 months 4 days ago
(13-Jun-2024)

4/4 (100%)

$-0.77 (-1.65%)

169

Hold

$53

$-0.78 (-1.45%)

$33

5 months 13 days ago
(04-Jun-2024)

8/8 (100%)

$5.65 (11.93%)

164

Buy

$42

$-11.78 (-21.90%)

$67

1 years 4 months 21 days ago
(27-Jun-2023)

6/12 (50%)

$13.87 (49.31%)

234

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Andrew Berens is most bullish on?

Potential upside of $9.61 has been obtained for ZYME (ZYMEWORKS . COMMON STOCK)

Which stock is Andrew Berens is most reserved on?

Potential downside of $2.22 has been obtained for AGIO (AGIOS PHARM)

What Year was the first public recommendation made by Andrew Berens?

On 2014

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?